MDEA
N-ethyl-3,4-methylenedioxyamphetamine
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MDEA (3,4-methylenedioxy-N-ethylamphetamine) — Eve — is a synthetic empathogen of the phenethylamine class. It is the N-ethyl homolog of MDMA, producing a similar but more sedating experience. It floods synapses with serotonin, dopamine, and norepinephrine,[1][2] producing the emotional warmth and openness that define the entactogen class.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
MDMA, MDA, serotonin releasing agents +1 moreMDMA, MDA, serotonin releasing agents, stimulants show less
Alexander Shulgin first synthesized MDEA in 1976 and described it in PiHKAL.[3] When MDMA was emergency-scheduled in 1985, MDEA circulated briefly as a legal substitute — until it was itself scheduled in October 1987.[4][5] It remains a Schedule I substance in the United States with no accepted medical use and no registered clinical trials.
Subjective effects include emotional warmth, mood elevation, mild stimulation, empathic openness, and subtle perceptual shifts.[6][7] The experience is quieter and more sedating than MDMA — more inwardly focused, with clear-headed warmth rather than outward social drive. Post-dose low mood from serotonin depletion, elevated heart rate, and residual fatigue are characteristic unsought effects.[8]
MDEA does not produce physical dependence; the acute dangers are overheating and cardiovascular stress.[4][8] Hot, crowded environments amplify the primary lethal pathway, and pre-existing heart conditions or MAOI drug combinations carry the highest individual risk.[7] The evidence base is exceptionally thin — one controlled human study and a handful of pharmacokinetic investigations constitute nearly the entire published literature.[6]
History[edit]
Discovery
Alexander Shulgin first synthesized MDEA in 1976 and documented it in PiHKAL.[3] He noted its similarity to MDMA — faster onset, shorter duration. In 1986, David Nichols coined the term "entactogen" to describe the pharmacological class encompassing MDEA, MDMA, and MDA.[1]
Scheduling and Prohibition
When MDMA was emergency-scheduled in May 1985, MDEA briefly circulated as a legal substitute.[4] The 1986 Federal Analog Act curtailed distribution by treating structural analogs of Schedule I substances as controlled when intended for human use. A 1987 JAMA report documenting five deaths associated with MDEA and MDMA use accelerated its formal Schedule I placement in October 1987.[4][5]
Modern Status
No registered clinical trials for MDEA have been conducted. Street tablets sold as "Ecstasy" in the late 1980s and 1990s often contained MDEA alongside other MDxx compounds.[6] Dedicated MDEA use has remained a niche within the broader entactogen market.
MDEA's street name Eve was paired with MDMA's colloquial name Adam — a branding choice, not a pharmacological relationship. The generic term "Ecstasy" came to encompass the entire MDxx class — MDA, MDMA, MDEA, and MBDB — and street tablets frequently contained mixtures of multiple ring-substituted amphetamines.[6]
Chemistry[edit]
MDEA belongs to the methylenedioxyphenethylamine family — a group of compounds defined by an oxygen-containing ring fused to the benzene core.[9] Its molecular formula is C₁₂H₁₇NO₂ (207.27 g/mol).
It is the N-ethyl homolog of MDMA: the same core structure, with an ethyl group replacing the methyl group on the nitrogen.[9]
Pharmacology[edit]
Mechanism of Action
MDEA releases serotonin, dopamine, and norepinephrine into synapses by entering nerve terminals via their respective transporters and triggering carrier-mediated release.[1][2] Serotonin release is the primary driver of the entactogenic experience, and MDEA's serotonin-releasing potency matches MDMA's.[10]
The key difference from MDMA is reduced dopamine release — MDEA achieves roughly 60% of MDMA's maximum dopaminergic output,[11] and is also the weakest MDxx compound at the NET.[12] This accounts for MDEA's more sedating, less stimulating character.[10]
Metabolism
MDEA breaks down through two primary pathways: conversion to MDA (an active metabolite) and breakdown to a catechol intermediate.[13] Drugs that block the CYP2D6 enzyme — including fluoxetine, paroxetine, and some HIV medications — can slow this breakdown, raising MDEA blood levels and prolonging effects.[13]
Neuroscience[edit]
Where It Acts
MDEA's strong serotonin release[10] is expected to quiet the brain's fear response — the mechanism central to MDMA's potential in PTSD treatment. Its partial dopamine release predicts attenuated activation of the brain's mesolimbic pathway, explaining the reduced stimulation and euphoria compared to MDMA.[11][6][7] inferred
Why It Matters
MDEA sits at the low end of the dopamine spectrum within the entactogen class[1][2] — enough for sustained emotional warmth, but too little for full stimulant-type reinforcement. The emotional "liking" response is preserved while the compulsive "wanting" drive is attenuated, consistent with reports of warmth without strong urges to redose.
Whether MDEA produces neuroplasticity like MDMA — relevant to any therapeutic potential — is unknown. All neurotoxicity data come from rat studies at doses far above typical human exposure,[14] and how that translates remains uncertain.[6] No neuroimaging studies of MDEA in humans have been conducted.
Subjective Effects[edit]
MDEA's experiential core is warmth. Emotional openness settles in without agitation or urgency — a gentle, inward quality that users describe as "easily controllable".[6] At higher doses, subtle perceptual shifts emerge, but the experience stays grounded.
Compared to MDMA, MDEA is more sedating and less outwardly driven.[7] It sits between MDMA's sociable energy and the quiet interiority of purely serotonergic compounds. The pro-social pull is present but muted; the emotional warmth is what remains.
Effect Grid
At common doses, the full entactogenic profile manifests: pronounced emotional warmth and openness, feelings of closeness and empathy, relaxation combined with mild psychomotor stimulation, and a pleasant, easily controllable mood state. Mild perceptual alterations — enhanced color saturation, increased tactile sensitivity — may be present without frank hallucination.
Cardiovascular effects become measurable: tachycardia, systolic blood pressure elevation, and pupil dilation are expected. Jaw tension (trismus), appetite suppression, and mild temperature dysregulation occur. Serum cortisol and prolactin elevate significantly.
The experience lasts 3-5 hours with a relatively gentle offset. Sleep may be difficult for several hours after effects subside.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Light sensitivity · Sound sensitivity · Color enhancement · Dreaming enhancement · Visual haze / noise · Tracers · Color alteration · Auditory distortion · Visual breathing · Visual drifting · Taste enhancement · Symmetrical texture repetition · Peripheral misidentification · Synesthesia
Visual haze / noise · Tracers · Color alteration · Auditory distortion · Visual breathing · Visual drifting · Taste enhancement · Symmetrical texture repetition · Peripheral misidentification · Synesthesia
Spontaneous body sensations · Tactile euphoria · Stimulation · Dehydration sensation · Excessive sweating · Bruxism · Wakefulness · Appetite suppression · Dry mouth · Tingling / electric sensations · Physical fatigue · Insomnia · Muscle tension · Laughter fits · Vibrations / buzzing · Bodily heaviness · Brain zaps · Sexual arousal enhancement · Nausea · Headache · Heart rate perception changes · Pain suppression · Dizziness · Restlessness · Nystagmus (eye wobbles) · Respiratory stimulation · Bodily lightness · Sexual arousal suppression · Abnormal heartbeat · Increased urination · Trembling · Motor control impairment · Muscle relaxation · Vomiting · Involuntary body movements
Dehydration sensation · Excessive sweating · Bruxism · Wakefulness · Appetite suppression · Dry mouth · Tingling / electric sensations · Physical fatigue · Insomnia · Muscle tension · Laughter fits · Vibrations / buzzing · Bodily heaviness · Brain zaps · Sexual arousal enhancement · Nausea · Headache · Heart rate perception changes · Pain suppression · Dizziness · Restlessness · Nystagmus (eye wobbles) · Respiratory stimulation · Bodily lightness · Sexual arousal suppression · Increased urination · Trembling · Motor control impairment · Muscle relaxation · Vomiting · Involuntary body movements
Cognitive fatigue · Introspection enhancement · Aesthetic enhancement · Thought connectivity · Humor enhancement · Memory suppression · Analysis suppression · Cognitive flexibility · Language enhancement · Novelty enhancement · Conceptual thinking · Cognitive impairment · Creativity enhancement · Motivation enhancement · Pattern recognition enhancement · Motivation suppression · Thought deceleration · Compulsive redosing urge · Thought acceleration · Increased nature relatedness · Memory replays · Memory fragmentation · Thought disorganization · Confusion · Focus enhancement · Information processing enhancement · Amnesia
Thought connectivity · Humor enhancement · Memory suppression · Analysis suppression · Cognitive flexibility · Language enhancement · Novelty enhancement · Conceptual thinking · Cognitive impairment · Creativity enhancement · Motivation enhancement · Pattern recognition enhancement · Motivation suppression · Thought deceleration · Thought acceleration · Increased nature relatedness · Memory replays · Memory fragmentation · Thought disorganization · Confusion · Focus enhancement · Information processing enhancement · Amnesia
Anxiety suppression · Simultaneous emotions · Irritability · Emotional lability · Dysphoria · Anhedonia · Catharsis · Empathy suppression · Anxiety · Mania
Emotional lability · Dysphoria · Anhedonia · Catharsis · Empathy suppression · Anxiety
Emotional susceptibility · Communication enhancement · Craving · Flow state · Compulsive behavior reduction · Sociability suppression · Social disconnection · Depersonalization · Derealization · Boundary dissolution · Identity alteration
Compulsive behavior reduction · Sociability suppression · Social disconnection · Depersonalization · Derealization · Boundary dissolution · Identity alteration
Timeline
First alerts emerge as a subtle shift in body awareness — mild warmth in the chest and a lightening of mood. Faster onset than MDMA was noted by Shulgin.
Emotional warmth builds progressively. Heart rate and blood pressure begin to rise. Mild anxiety or restlessness may accompany the transition as effects intensify.
Full entactogenic state: emotional openness, feelings of closeness, relaxation with mild stimulation. Cardiovascular effects (tachycardia, systolic hypertension) and neuroendocrine changes (cortisol, prolactin elevation) are maximal.
Effects remain present but gradually diminish in intensity. The emotional warmth persists with decreasing stimulation. A sedating, "stoning" quality may predominate during the plateau.
Progressive return to baseline. Mild fatigue and emotional flatness emerge as serotonin stores deplete. Appetite may begin to return.
Residual mood changes — either gentle positivity or mild dysphoria — may persist for 6–12 hours. Some users report a low-mood period over the following 1–2 days consistent with serotonin depletion.
⚠ Do not drive or operate heavy machinery until after a full night of sleep, as residual cognitive and psychomotor impairment may persist beyond subjective awareness of effects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- MDMA · MDA · serotonin releasing agents
Toxicity
Acute Toxicity
No lethal dose has been established for MDEA in any species. safety citation needed
Overheating is the primary acute danger. MDEA raises body temperature in a dose-dependent way — requiring roughly twice the dose of MDMA for equivalent heat effect in animal models[14][10] — but dangerous fevers and potentially fatal heat events are documented in human users.[7]
Heart and Circulation
A controlled study of 140 mg oral MDEA in healthy volunteers produced significant increases in heart rate and blood pressure.[8] Fatal heart rhythm disturbances have occurred in individuals with underlying heart conditions who used MDEA or MDMA.[4]
Muscle Breakdown and Clotting Failure
Severe muscle breakdown and widespread clotting failure are documented fatal complications of MDxx poisoning, particularly when combined with overheating.[7]
Fatal Cases
A 1987 JAMA report documented five deaths linked to MDMA and MDEA use, three involving people with pre-existing heart disease.[4] A Belgian forensic review of amphetamine-related deaths (1976–2004) included MDEA cases, with acute cardiopulmonary failure as the most common cause.[15] A UK analysis of 605 ecstasy-related deaths (1997–2007) found victims had a mean age of 28.3 years.[16]
Liver Damage
Liver damage is a recognized MDxx class risk,[17] but no MDEA-specific cases have been reported. This risk is inferred from structural similarity to MDMA. inferred
Low Sodium
Dangerously low sodium from excess water intake is documented for MDMA but not specifically for MDEA. The risk is inferred from shared pharmacology. inferred
Psychological Risks
MDEA is described as "easily controllable",[6] suggesting lower acute psychological risk than serotonergic hallucinogens. No controlled studies of MDEA's psychological adverse effects exist — the absence of data does not establish safety.
Class-level risks inferred from the MDxx series include post-dose low mood from serotonin depletion, anxiety during onset, and potential worsening of depression in vulnerable individuals. No MDEA-specific data on long-term psychiatric outcomes exist. inferred
Tolerance and Dependence
No MDEA-specific tolerance or dependence studies have been published.[6][18] The primary mechanism — inferred from MDMA — is serotonin depletion: MDEA empties serotonin stores acutely, producing a diminished response on subsequent dosing until stores rebuild over several days. Cross-tolerance extends to MDMA and MDA. inferred
MDEA's partial dopamine release predicts lower reinforcement potential than MDMA, but this has not been empirically tested. No abuse liability studies have been conducted.
Drug Interactions
Serotonin Overload
The most dangerous interactions involve compounds that raise serotonin through complementary routes. MAO inhibitors (phenelzine, tranylcypromine, selegiline, moclobemide) block serotonin breakdown; combined with MDEA's large serotonin release, this can produce a life-threatening emergency involving dangerous overheating, muscle rigidity, and cardiovascular collapse. safety citation needed
Tramadol inhibits serotonin reuptake while also acting on opioid receptors, carrying lethal risk through serotonin overload and seizure threshold lowering.[19] Combining MDEA with MDMA creates dangerous additive serotonin load and compounds overheating risk.[6][14]
Cardiovascular Compounding
Cocaine combined with MDEA carries lethal risk through combined cardiovascular strain — both substances independently raise heart rate, blood pressure, and cardiac oxygen demand.[4]
Metabolism-Based Interactions
Drugs that block the CYP2D6 enzyme — including SSRIs (fluoxetine, paroxetine), bupropion, and some HIV medications (ritonavir) — may significantly raise MDEA blood levels by blocking its main breakdown pathway, intensifying and prolonging effects.[13] inferred
Contraindications
Pre-existing heart conditions — arrhythmia history, structural heart disease, long QT syndrome — are absolute contraindications based on documented fatality risk.[4]
Concurrent MAO inhibitor therapy is an absolute contraindication for all serotonin-releasing agents due to fatal serotonin overload risk. safety citation needed
Concurrent tramadol use carries lethal interaction risk.[19]
Concurrent cocaine use carries lethal interaction risk through combined cardiovascular strain.[4]
Hot, crowded environments dramatically increase overheating risk and are the primary contextual risk factor for MDxx fatalities.[7]
CYP2D6 poor metabolizer status may be a relative contraindication, as impaired metabolism could substantially raise MDEA blood levels and prolong effects. No pharmacogenomic dosing data exist. inferred
Harm Reduction[edit]
Forms & Identification
MDEA typically appears as the hydrochloride salt in pressed tablets or crystalline powder. A structural regioisomer exists with identical molecular weight and similar drug screen results — laboratory confirmation (GC/MS or HPLC) is the only definitive identification method.[20]
Street "Ecstasy" tablets have historically contained variable mixtures of MDxx compounds.[6] Reagent testing can rule out some dangerous substitutions but cannot distinguish MDEA from MDMA or MDA.
Guidelines
- Test all material with reagent kits before use — visual identification alone cannot confirm MDEA
- Start with the lower end of the common dose range and wait at least 90 minutes before considering whether to redose
- Avoid redosing; serotonin stores deplete rapidly, and additional doses increase cardiovascular and neurotoxic risk without proportional return of desired effects
- Stay cool — take regular breaks from physical activity, seek ventilated areas, and monitor body temperature
- Drink water at a moderate pace (approximately 250 mL per hour when active); do not overhydrate, as dangerously low sodium is a recognized MDxx risk
- Eat a light meal several hours before and prepare recovery nutrition for afterward
- Plan for a full day of rest following use to allow serotonin recovery
Set & Setting
MDEA's effects are described as "easily controllable",[6] with lower psychological volatility than serotonergic hallucinogens. Cool, well-ventilated environments with water access are essential — hot, crowded settings dramatically amplify overheating risk, the primary contextual danger for the MDxx class.[7]
A trusted companion and familiar surroundings reduce the likelihood of anxiety during onset.
Aftercare & integration. The days after MDEA use involve serotonin recovery. Low mood, fatigue, and irritability in the 24–72 hours afterward reflect depleted serotonin stores, not lasting harm. Prioritize sleep, nutritious food, gentle activity, and social connection during this window.
Avoid MDEA or other serotonin-releasing substances for at least several weeks to allow full neurochemical recovery. Repeated use on consecutive days compounds neurotoxic risk without meaningful return of desired effects.
If low mood persists beyond a week, or if the experience surfaced difficult emotional material, professional support from a therapist familiar with substance-related concerns is appropriate.
Recovery & Support
MDEA's lower reinforcement potential relative to MDMA may reduce compulsive use patterns, but psychological habituation to the entactogenic state can develop with any substance that reliably produces emotional warmth and connection.
Patterns worth examining include using MDEA to access emotional states that feel unavailable sober, escalating frequency despite diminishing returns, or difficulty engaging socially without the substance. Peer support communities, harm reduction organizations, and addiction counselors experienced with club drugs can provide appropriate support.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Body temperature felt through clothing, chest pain, seizures, loss of consciousness, or extreme confusion all require immediate medical help. Mild anxiety, nausea, or elevated heart rate can typically be managed with reassurance, a cool environment, and rest.
Immediate steps:
- 1. Call emergency services if the person is unconscious, seizing, experiencing chest pain, or dangerously overheated
- 2. Move the person to a cool, quiet area
- 3. If unconscious but breathing, place in the recovery position (on their side)
- 4. Remove excess clothing and apply cool water to the skin if overheating is suspected
- 5. Do not restrain the person unless they are in immediate danger of self-harm
- 6. Do not induce vomiting
What to tell the dispatcher: Name the substance (MDEA or "ecstasy-type drug"), estimated amount, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
MDEA is a controlled substance in all major jurisdictions, classified at the highest restriction levels following documented fatalities associated with its use.[4]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (CSA) | Effective October 1987. Covered by Federal Analog Act (1986) prior to explicit listing. No accepted medical use; high abuse potential.[4][5] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under the generic substituted phenethylamine class provision.[5] |
| Germany | Anlage I (BtMG) | Non-tradable; permitted only for scientific purposes under specific government authorization.[5] |
| Canada | Schedule I (CDSA, 1996) | Controlled as explicit listing or structural analog under the Controlled Drugs and Substances Act.[5] |
| Australia | Controlled substance | Prohibited under the Poisons Standard and Therapeutic Goods Act framework.[5] |
| European Union | Varies by member state | All EU countries control the MDxx class under national legislation. No EU-wide specific scheduling instrument exists separate from national laws. |
Analog Act Considerations
In the United States, MDEA's structural similarity to MDMA made it effectively controlled from the passage of the Federal Analog Act (21 U.S.C. § 813) in 1986, before its explicit Schedule I placement in 1987. The Act treats any substance substantially similar in structure or pharmacological effect to a Schedule I or II substance as equivalently controlled when intended for human consumption. This framework remains relevant for novel MDxx analogs not yet explicitly scheduled.
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Verify current laws in the relevant jurisdiction before traveling internationally or making legal decisions.
references
- [1] ^abcdNichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens — Journal of Psychoactive Drugs PMID:2880944
- [2] ^abcNichols DE (2022) Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated — Frontiers in Psychiatry doi:10.3389/fpsyt.2022.863088
- [3]
- [4]
- [5]
- [6]